NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

georgebailey,

It gets better. Not only is autologous accounted for but matching donors are listed in the patents as well as knowledge of who responders will be prior to treatment based upon creating required post activation/maturation DC characteristics needed to overcome cancer defenses. This not only identifies but also maximizes the number of patients qualifying to receive treatment. Having manufacturing and product release obstacles overcome prior to advancement of Direct creates the time for ramp up runway needed when approval(s) come.
One last economic balance consideration is that L basically invites others to join in search of best combos and “franchise” experience while Direct likely eliminates much of that need as a much bigger disruptor. Best wishes.